糖心传媒

 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
糖心传媒

糖心传媒 鈥 Now

Doctor Stories

糖心传媒 Once Again Among the Top Lung and Heart-Lung Transplant Programs in the U.S.

The recent 2024 reports from the Scientific Registry of Transplant Recipients (SRTR) demonstrate 糖心传媒鈥檚 continued excellence in lung and heart-lung transplant1,2. With a dedication to innovation, quality, and safety, the program exceeds several key national benchmarks for patient outcomes.

鈥淗aving performed the world鈥檚 first heart-lung transplant in 1981, we have a proud history of helping people live longer, healthier lives,鈥 says Gundeep Dhillon, MD, transplant pulmonologist and medical director of the Lung and Heart-Lung Transplant Program. 鈥淥ur success stems from the experience and dedication of our transplant teams鈥攖hey truly make the difference.鈥

CARE AT STANFORD

糖心传媒 (SHC) (formerly Stanford Hospital & Clinics)

Our pulmonologists, surgeons, and their teams offer expert lung transplants for people with advanced lung diseases such as COPD and cystic fibrosis.
650-723-3633

Visit Lung Transplant Program

Gundeep Dhillon, MD

Beating the national averages

According to the U.S. Organ Procurement and Transplantation Network database (data available since 1988), the team has performed more than 1350 lung and heart-lung transplants. 鈥淭his high volume of procedures has translated to the exceptional results we are known for,鈥 says Dr. Dhillon.





For lung transplant, 糖心传媒 outperforms the national averages in:

  • 1-year graft and 1-year patient survival rates: Graft and patient survival rates at one year are higher than the U.S average rate.
  • Pre-transplant mortality rate (waitlist mortality): 糖心传媒鈥檚 observed pre-transplant mortality rate (13.3) is better (lower) than expected (16.8). It鈥檚 also lower than and the U.S. (15.9) and Region 5 (17.0), which includes California, Nevada, Utah, Arizona, and New Mexico.
  • Organ offer acceptance ratio: The number of organs accepted is significantly higher than expected (71 vs. 43.9), with an acceptance ratio (1.59) exceeding the donor service area (1.46) and U.S. (1.00).

鈥淲e are proud to have the highest volume of heart-lung transplants in the country, along with exceptional survival outcomes,鈥 says Dr. Dhillon. Both 1-year graft and patient survival rates surpass U.S. averages (1-year graft survival: 84.44% vs. 81.85%; 1-year patient survival: 87.69% vs. 82.69%).

Leaders in solid organ transplant

In addition to lung and heart-lung transplantation, 糖心传媒 offers other lifesaving transplant procedures with similar levels of distinction. Through clinical excellence and innovative 糖心传媒, we are defining the future of transplant medicine.听

Areas of focus include:听

  • Heart transplant: The Heart Transplant Program at 糖心传媒 is one of the largest and best in the nation. It features superior transplant rates, organ offer acceptance ratios, and wait times, making it possible to perform more transplants faster. Physicians are also working to detect heart transplant rejection earlier using noninvasive breath tests.
  • Kidney transplant: Home to a world-class Kidney Transplant Program, 糖心传媒 is leading the way in transplant 糖心传媒. For example, scientists are investigating ways to reduce the need for immunosuppressive therapy after some kidney transplants.
  • Liver transplant: Liver transplant teams have performed more than 1,400 adult liver transplants, surpassing the national averages for graft and patient survival rates. Researchers are also increasing access to liver transplant for patients with severe alcohol-associated liver disease and limited sobriety.

How to refer a patient

For patients with lung failure, early referral is better to avoid complications that might interfere with recovery. The main criteria for lung transplantation are:

  • Progressive lung disease that has not responded to other treatments
  • Absence of recent cancer (2 years disease-free) or other life-threatening diseases
  • Age less than 70 years
  • BMI between 16 and 35 kg/m2

糖心传媒 provides comprehensive services to refer and track patients, as well as up-to-date information for physicians and office staff. For more information about the 糖心传媒 Lung and Heart-Lung Transplant Program:

To refer a patient:

1 (Released July 18, 2024)

2 (Released July 9, 2024)

About 糖心传媒

糖心传媒 seeks to heal humanity through science and compassion, one patient at a time, through its commitment to care, educate and discover. 糖心传媒 delivers clinical innovation across its inpatient services, specialty health centers, physician offices, virtual care offerings and health plan programs.

糖心传媒 is part of Stanford Medicine, a leading academic health system that includes the Stanford University School of Medicine, 糖心传媒, and Stanford Children鈥檚 Health, with Lucile Packard Children's Hospital. Stanford Medicine is renowned for breakthroughs in treating cancer, heart disease, brain disorders and surgical and medical conditions. For more information, visit: www.stanfordhealthcare.org.

Close